A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Idiopathic Pulmonary Fibrosis(IPF)

In brief

The purpose of this study is to evaluate the safety, tolerability, PK and immunogenicity of SV001 in patients with idiopathic pulmonary fibrosis.

Key facts

Study ID

NCT07121413

Run by

Shanghai Synvida Biotechnology Co.,Ltd.

People needed

48

Starts

2025-11-04

Expected to finish

2026-12-31

Last updated by the study team

2026-02-11

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with a confirmed diagnosis of IPF and pulmonary function meeting the protocol-specified criteria;
• Subjects must agree to use highly effective contraception during the study and for 6 months after the last administration of the study drug;
• Subjucts must be able to understand the study, voluntarily provide written informed consent, and be willing and able to comply with all study-related procedures.

You may not qualify if…

• Subjects with a history of drug or other allergies, or those judged by the investigator to be potentially allergic to the study drugs;
• Presence of any other clinically significant pulmonary diseases besides IPF at screening;
• Any known contraindications to performing pulmonary function tests at screening;
• Respiratory or systemic infections requiring anti-infective therapy within 1 month prior to randomization;
• Acute exacerbation of IPF within 4 months prior to randomization;
• Use of any medication known to cause or worsen pulmonary fibrosis, as assessed by the investigator, within 3 months prior to screening;
• History of smoking within 3 months prior to screening, or unwillingness to quit smoking throughout the study period;
• Presence of clinically significant cardiovascular, cerebrovascular, hematological, neurological, psychiatric, or metabolic disease at screening, or plans for major surgery during the study period;
• Presence of specified abnormal laboratory test results at screening;
• Evidence of renal impairment or end-stage renal disease requiring dialysis at screening;
• Active hepatitis virus infection; history of acquired or congenital immunodeficiency disease;
• History of malignancy within 5 years prior to screening;
• Difficulty with venipuncture or a history of needle phobia or blood phobia;
• Positive pregnancy tests or currently lactating at screening;
• Participation in another clinical trial and receipt of other investigational drugs within 3 months prior to randomization;
• Any other condition that the investigator consider unsuitable for participation in the study.

Where it is running

• Sichuan Provincial People's Hospital — Chengdu, China (enrolling)
• The First Affiliated Hospital of Guangzhou Medical University — Guangzhou, China (enrolling)
• Hangzhou First People's Hospital — Hangzhou, China (enrolling)
• The First Affiliated Hospital of Nanchang University — Nanchang, China (enrolling)
• Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School — Nanjing, China (enrolling)
• The Affiliated Hospital of Inner Mongolia Medical University — Neimeng, China (enrolling)
• Dongfang Hospital Affiliated to Tongji University — Shanghai, China (enrolling)
• Huadong Hospital Affiliated to Fudan University — Shanghai, China (enrolling)
• Shanghai Pulmonary Hospital — Shanghai, China (enrolling)
• General Hospital of Tianjin Medical University — Tianjin, China (enrolling)
• The Affiliated Hospital of Xuzhou Medical University — Xuzhou, China (enrolling)
• Henan Provincial People's Hospital — Zhengzhou, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.